More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$211.18B
EPS
-3.15
P/E ratio
--
Price to sales
6.15
Dividend yield
1.926%
Beta
0.349701
Previous close
$167.58
Today's open
$166.12
Day's range
$165.72 - $171.36
52 week range
$116.88 - $176.58
show more
CEO
Daniel P. O¿Day
Employees
17000
Headquarters
Foster City, CA
Exchange
Nasdaq Global Select
Shares outstanding
1.24B
Issue type
Common Stock
Healthcare
Pharmaceuticals
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Zacks Investment Research • 10 hours ago

Worried investors are paying up for these stocks — some with up to 49% upside, analysts say
Defensive sectors have beaten the S&P 500 by a wide margin in recent months, even though they are priced much higher relative to earnings estimates than the index.
Market Watch • 9 hours ago

Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy Headwind
Gilead Sciences NASDAQ: GILD expects its expanding HIV prevention portfolio and a potential new cell therapy for multiple myeloma to support growth, even as a negotiated price change for its HIV treatment Biktarvy creates an anticipated $1.5 billion headwind in 2028, Chief Financial Officer Andy Dickinson said at an investor conference.
MarketBeat • Nov 17, 2026

Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation Drugs
Gilead Sciences NASDAQ: GILD expects HIV and oncology to drive growth through the rest of the decade while it builds an inflammation business for the 2030s, executives said at a London healthcare conference.
MarketBeat • Nov 17, 2026

Gilead Sciences, Inc. (GILD) Presents at UBS Global Biopharma Conference 2026 Transcript
Gilead Sciences, Inc. (GILD) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

Gilead Sciences, Inc. (GILD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Gilead Sciences, Inc. (GILD) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

Suffolk Celebrates Completion of Gilead Sciences Research Center With Ribbon Cutting
FOSTER CITY, Calif.--(BUSINESS WIRE)--Suffolk, one of the most innovative and successful builders in the country, recently joined Gilead Sciences to celebrate the completion of its new Research Center in Foster City, California. Through close collaboration with Gilead, Suffolk delivered a highly specialized and adaptable research environment designed to evolve alongside the company's scientific needs, creating laboratory spaces that can accommodate new research teams, equipment and technologies.
Business Wire • Nov 17, 2026

Gilead Expands Access to Investigational Obeldesivir for Ebola Bundibugyo Virus Disease Through Voluntary Licensing
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has signed royalty-free voluntary licensing agreements with three generic manufacturers to support potential future access to its investigational antiviral obeldesivir as post-exposure prophylaxis (PEP) for Ebola Bundibugyo virus disease (BVD). The agreements cover 127 primarily low- and lower-middle-income countries, consistent with the geographic scope of Gilead's existing voluntary licensing ag.
Business Wire • Nov 16, 2026

Can Gilead Sciences' HIV Business Fuel Sustainable Long-Term Growth?
GILD's HIV franchise gains momentum as Yeztugo sales surge, Biktarvy maintains market leadership and an expanding pipeline strengthens long-term growth prospects.
Zacks Investment Research • Nov 12, 2026

3 Pharmaceutical Stocks That Offer Safety and Growth
Market volatility is unpleasant, but it's important that investors don't force themselves into a false choice between safety and growth. Over the last two years, technology stocks, particularly AI stocks, have driven strong portfolio gains for active and passive investors.
MarketBeat • Nov 12, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Gilead Sciences Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.